We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|Cellular Assay (CA)||1 Antibodies|
|Dot Blot (DB)||192 Antibodies|
|ELISA (Capture)||1 Antibodies|
|Enzyme Immunoassay (EIA)||17 Antibodies|
|Flow Cytometry (FACS)||133 Antibodies|
|Functional Studies (Func)||5 Antibodies|
|Immunoassay (IA)||1 Antibodies|
|Immunochromatography (IC)||5 Antibodies|
|Immunocytochemistry (ICC)||12 Antibodies|
|Immunoelectron Microscopy (IEM)||6 Antibodies|
|Immunofluorescence (IF)||215 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||93 Antibodies|
|Immunohistochemistry (IHC)||317 Antibodies|
|Immunohistochemistry (Acetone-fixed) (IHC (af))||5 Antibodies|
|Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))||2 Antibodies|
|Immunohistochemistry (Formalin-fixed Sections) (IHC (f))||3 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||45 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||182 Antibodies|
|Antigen||V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) Antibodies|
|Conjugate||This HER2 antibody is conjugated to APC Alternatives|
Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)
|6 references available|
|Supplier||Log in to see|
Product Details anti-HER2 AntibodyTarget Details HER2 Application Details Handling References for anti-HER2 Antibody (ABIN2658634) Images
|Purification||The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.|
Target Details HER2Product Details anti-HER2 Antibody Application Details Handling References for anti-HER2 Antibody (ABIN2658634) Images back to top
|Alternative Name||CD340 (ERBB2 Antibody Abstract)|
|Background||CD340 is also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. It is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain and has an approximate molecular weight of 185 kD. CD340 contains three furin repeats and two cheY homologous receiver domains in the extracellular region (ECR). The HER2/erbB2 protein is expressed on many tumor cells, including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow mesenchymal stem cells. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression, this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Overexpression of erbB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).|
|Pathways||RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-HER2 Antibody Target Details HER2 Handling References for anti-HER2 Antibody (ABIN2658634) Images back to top
|Application Notes||Optimal working dilution should be determined by the investigator.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-HER2 Antibody Target Details HER2 Application Details References for anti-HER2 Antibody (ABIN2658634) Images back to top
|Buffer||Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Protect from prolonged exposure to light. Do not freeze.|
|Storage Comment||The antibody solution should be stored undiluted between 2°C and 8°C.|
References for anti-HER2 Antibody (ABIN2658634)Product Details anti-HER2 Antibody Target Details HER2 Application Details Handling Images back to top
Leone, Perissinotto, Cavalloni et al.: "Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells." in: Journal of leukocyte biology, Vol. 74, Issue 4, pp. 593-601, 2003 (PubMed).
Pegram, Finn, Arzoo et al.: "The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells." in: Oncogene, Vol. 15, Issue 5, pp. 537-47, 1997 (PubMed).
Bühring, Sures, Jallal et al.: "The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia." in: Blood, Vol. 86, Issue 5, pp. 1916-23, 1995 (PubMed).
Bargmann, Hung, Weinberg: "The neu oncogene encodes an epidermal growth factor receptor-related protein." in: Nature, Vol. 319, Issue 6050, pp. 226-30, 1986 (PubMed).
Akiyama, Sudo, Ogawara et al.: "The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity." in: Science (New York, N.Y.), Vol. 232, Issue 4758, pp. 1644-6, 1986 (PubMed).
Slamon, Godolphin, Jones et al.: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer." in: Science (New York, N.Y.), Vol. 244, Issue 4905, pp. 707-12, 1989 (PubMed).
ImagesProduct Details anti-HER2 Antibody Target Details HER2 Application Details Handling References for anti-HER2 Antibody (ABIN2658634) back to top